Maria Emilia Di Francesco

Bio: Maria Emilia Di Francesco is an academic researcher from University of Texas System. The author has contributed to research in topics: Glutaminase & Cancer. The author has an hindex of 3, co-authored 4 publications receiving 35 citations.

Glutaminase inhibitor therapy

Abstract: Disclosed herein are methods of treating a subject having an altered NRF2/KEAP1 pathway, and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject.

Gls1 inhibitors for treating disease

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.

Cyclic di-nucleotide compounds and methods of use

Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase

Abstract: Kidney-type glutaminase (GLS), the first enzyme in the glutaminolysis pathway, catalyzes the hydrolysis of glutamine to glutamate. GLS was found to be upregulated in many glutamine-dependent cancer cells. Therefore, selective inhibition of GLS has gained substantial interest as a therapeutic approach targeting cancer metabolism. Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethyl sulfide (BPTES), despite its poor physicochemical properties, has served as a key molecular template in subsequent efforts to identify more potent and drug-like allosteric GLS inhibitors. This review article provides an overview of the progress made to date in the development of GLS inhibitors and highlights the remarkable transformation of the unfavorable lead into “druglike” compounds guided by systematic SAR studies.

Combination therapy with glutaminase inhibitors

Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an anticancer agent such as an enzyme inhibitor (such as a kinase inhibitor), a mitotic inhibitor, a DNA-modifying agent, or a cytidine analog. The invention further relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases that are resistant to one or more anticancer agents.

Heterocyclic inhibitors of rho kinase

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.